Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916802 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(1 year, 30 days ago) | |
US7196205 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Jun, 2026
(3 years from now) | |
US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7615573 | GENZYME CORP | Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
Apr, 2022
(1 year, 30 days ago) | |
US7253185 | GENZYME CORP | Amino ceramide-like compounds and therapeutic methods of use |
Apr, 2022
(1 year, 30 days ago) | |
US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(7 years from now) | |
US10888544 | GENZYME CORP | Methods for treating Gaucher disease |
Dec, 2038
(15 years from now) |
Market Authorisation Date: 19 August, 2014
Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat ...
Dosage: CAPSULE;ORAL
44
United States
13
Japan
12
European Union
7
Spain
7
Canada
7
Portugal
6
Denmark
6
China
6
Brazil
6
Korea, Republic of
6
Cyprus
5
Australia
4
Hong Kong
4
Poland
4
Israel
3
RS
3
Singapore
3
Argentina
3
EA
3
New Zealand
3
Croatia
3
Taiwan
3
Mexico
3
Slovenia
2
Austria
2
Dominican Republic
2
Peru
2
Chile
2
Ecuador
2
Lithuania
2
Hungary
1
Philippines
1
Malaysia
1
Russia
1
Ukraine
1
Morocco
1
ME
1
Nicaragua
1
San Marino
1
Belgium
1
Guatemala
1
Costa Rica
1
Colombia
1
Luxembourg
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic